(Q34276023)

1 August 2017

1 reference

title

Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis (English)

1 reference

1 August 2017

1 reference

Keystone EC

1

1 reference

1 August 2017

publication date

1 May 2001

1 reference

Rheumatic Diseases Clinics of North America

1 August 2017

published in

1 reference

1 August 2017

volume

27

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

427-443

1 reference

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

The biology of cachectin/TNF--a primary mediator of the host response

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970211-8

7 January 2021

10.1016/S0889-857X(05)70211-8

Identifiers

DOI

1 reference

1 August 2017

1 reference